Novavax (NVAX) Revenue Growth (5y) (2015 - 2026)
Powered by 
Analysis
Novavax (NVAX) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Novavax | 1.67 Bn | 949.38 Mn | 42.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.24% |
| Mar 31, 2026 | -20.78% |
| Dec 31, 2025 | -12.05% |
| Sep 30, 2025 | -14.81% |
| Jun 30, 2025 | 46.43% |
| Mar 31, 2025 | 187.79% |
| Dec 31, 2024 | 58.54% |
| Sep 30, 2024 | 102.09% |
| Jun 30, 2024 | 162.13% |
| Mar 31, 2024 | 88.14% |
| Dec 31, 2023 | 116.49% |
| Sep 30, 2023 | 89.09% |
| Jun 30, 2023 | 108.49% |
| Mar 31, 2023 | 53.01% |
| Dec 31, 2022 | 102.83% |
| Sep 30, 2022 | 144.82% |
| Jun 30, 2022 | 94.20% |
| Mar 31, 2022 | 162.21% |
| Dec 31, 2021 | 110.32% |
| Sep 30, 2021 | 78.19% |